Roche to Acquire PathAI for $750M Upfront
Roche (OTCQX: RHHBY) agreed to acquire PathAI to expand its digital pathology and…
Genentech fenebrutinib cuts relapsing MS relapses 51%-59%
04/21/2026 – 07:15 PM Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib…
Genentech brings 45 ophthalmology abstracts to ARVO 2026
04/30/2026 –…
Roche to present 45 ophthalmology studies at ARVO
Roche (OTCQX: RHHBY) will present more than 45 abstracts at ARVO 2026 (3–7…
Roche Highlights Gazyva Progress, Reports Data on Enspryng, MS Drug
Roche RHHBY announced that the FDA has accepted its supplemental application for Gazyva/Gazyvaro (obinutuzumab) to treat systemic lupus…
Roche Q1 sales rise 6% CER, outlook confirmed
Roche (OTCQX: RHHBY) reported Group sales of CHF 14.7bn in Q1 2026: +6%…
Roche Highlights Gazyva Progress, Reports Data on Enspryng, MS Drug
Roche RHHBY announced that the FDA has accepted its supplemental application for Gazyva/Gazyvaro (obinutuzumab) to treat systemic lupus…
Roche fenebrutinib cuts RMS relapses 51%-59%
Roche (OTCQX: RHHBY) reported that investigational fenebrutinib met primary endpoints in Phase III…
Roche ENSPRYNG cuts MOGAD relapse risk 68%
Roche (OTCQX: RHHBY) reported Phase III METEOROID results showing ENSPRYNG (satralizumab) reduced risk…
Roche lupus drug Gazyva gets FDA filing acceptance
Roche (OTCQX: RHHBY) said the FDA accepted its supplemental BLA for Gazyva/Gazyvaro (obinutuzumab)…
RHHBY to Invest $1.25B to Boost Manufacturing Footprint in US
Less than a month after announcing a $50 billion investment in its U.S. operations over the next five…
Genentech persevERA breast cancer trial misses PFS goal
03/09/2026 –…